A new study published online in the Journal of Trauma and Acute Care Surgery in March 2020 reports that the anticoagulation drug tPA could be a potential aid in managing respiratory failure in ...

The clot-busting drug tissue plasminogen activator (tPA) is currently the only FDA-approved therapy for acute stroke. However, increasing evidence suggests that tPA can also contribute to excitotoxic ...

Adult patients with sickle cell disease who experience a stroke caused by a clot (i.e., ischemic strokes) can be treated safely with tissue plasminogen activator if they qualify, report investigators.

Please provide your email address to receive an email when new articles are posted on . NEW YORK — Vitrectomy using balanced saline solution without tissue plasminogen activator is effective for ...

The window of safety and efficacy for administering tissue plasminogen activator (tPA), the only FDA-approved medication for stroke, is less than four hours. For patients with “wake-up stroke,” ...

The drug tPA (tissue-type plasminogen activator) can break up the blood clots that cause strokes and heart attacks, but it can also loosen the blood-brain barrier and generate inflammation in the ...

Medicare for the first time will soon begin reimbursing hospitals specifically for the administration of tissue plasminogen activator in ischemic stroke patients, marking "what promises to create a ...

Commenting on the study's results, lead author Robert J. Adams, MD, said, "Having sickle cell disease did not adversely affect any of the indicators we measured." New research has found that tissue ...

The antithrombic agent might disrupt catheter-lumen biofilms, which could predispose to infection. Intra-dialytic instillation of tissue plasminogen activator (tPA) may be associated with increased ...

About 87 percent of all strokes are ischemic, meaning they’re caused by a blood clot in the brain. For more than 20 years, the standard of care has been a drug called TPA. But now, some doctors are ...

In the largest report on acute stroke in sickle cell disease to date, researchers at the Medical University of South Carolina and elsewhere provide the first systemic evidence for the safe use of tPA ...